DeVry Education Group Inc. (DV)

FQ4 Review; Maintain Neutral



Maintaining Neutral rating. Results remain weak with an adj. operating loss at one segment (BTM), and material y/y operating income declines at the other two segments. Implied FQ1-16 guidance is also well below consensus. F'16 guidance appears more encouraging, as does (what we consider lofty) multi-year growth targets, but our confidence in both is low. Maintaining Neutral rating; company in midst of next stage of transformation (of what has been multi-year process) in what we view as secularly challenged industry.

- FQ4 results very weak, and below consensus. Adj. EBIT was -21% y/y, 5% below consensus, while revenue was -2.5% y/y, 1.6% below consensus. Adj. EPS was \$0.57, below \$0.62 consensus.
- All three segments weak, and pockets of growth accompanied by margin contraction.
 - Medical & Healthcare adj. EBIT -10% y/y despite 8% revenue growth.
 - International & Professional Education adj. EBIT -8% y/y despite 16% revenue growth.
 - BTM reported a slight quarterly adj. EBIT loss.
- New enrollment materially as expected, with a few pockets of relative strength, although metric is volatile on period-to-period basis, and some of the areas of good percentage growth were off a relatively small base.
 - Early progress ameliorating clinical capacity constraints at FNP program encouraging (constraints had contributed to Chamberlain new enrollment deceleration).
- F'16 guidance back-end loaded and expense savings/margin dependent.
 - **FQ1-16 guidance** calls for 5% y/y revenue decline with adj. opex down 2-3% y/y -- implies revenue ~1.4% below prior consensus and adj. EBIT ~16-29% below prior consensus.
 - **F'16 guidance:** adj. EPS ~flat vs. \$2.49 in F'15 (F'16 consensus was \$2.50), while revenue guidance of -5% y/y is ~3.7% below consensus.
- Fine-tuning our estimates (we remain below implied guidance). We have low confidence in back-end loaded F'16 guidance and are modeling an adj. operating loss in the BTM segment (although timing of expected restructuring-related expense savings provides some credibility to back-end loaded guidance).
- We hope for supporting justification for multi-year growth targets at Sept. 16 Investor Day. Targets include mid-single-digit organic revenue growth and mid-teens EBITDA growth (through F'20). Our initial view is that the targets are highly aggressive.
- Reducing price target to \$30, maintaining Neutral. DV is in midst of the next stage of its transformation (of what has been multi-year process) in what we view as secularly challenged industry.

DV operates DeVry University, Chamberlain College of Nursing, Carrington College, DeVry Brazil, DeVry Medical International, and Becker Professional Review.

LOWERING PRICE TARGET

1-Year Price Chart



Stock Data

Rating:	Neutral
Suitability:	Higher Risk
Price Target/Previous:	v \$30/\$33
Price (8/18/15):	\$27.05
Market Cap (mil):	\$1,764
Shares Out (mil):	65.2
Average Daily Vol (mil):	0.74
Dividend Yield:	1.3%

Estimates

FY Jun	2014A	2015A	2016E
Q1	0.22 A	0.47 A	0.31 E
Q2	0.80 A	0.75 A	0.62 E
Q3	0.87 A	0.70 A	0.75 E
Q4	0.73 A	0.57 A	0.62 E
Fiscal EPS	2.62 A	2.49 A	2.29 E
Previous Est		2.58 A	2.33 E
Fiscal P/E	10.3x	10.9x	11.8x
Calendar EPS	2.82 A	2.19 E	
Previous Est		2.41 E	
Calendar P/E	9.6x	12.4x	

Chart/Table Sources: Factset and Baird Data

EPS (Net): 2013 results, as presented above, are estimated for the planned divestiture of Advanced Academics EPS (Net): Results, as presented, exclude unusual items.

Please refer to Appendix - Important Disclosures and Analyst Certification

Details

Our reduced \$30 price target reflects 13.1x our F'16 EPS estimate, in line with DV's three-year historical average NTM P/E (range of 10.0x-17.2x). Our price target also reflects 10.6x our cash-adjusted F'16 EPS estimate (plus \$5.63/sh. in cash).

F4Q15 (June) Results

		Quarterl	y Results					Percer	nt of Revenu	ie
	F4Q15	F4Q14	Change	Baird	Variance	Cons.	Variance	F4Q15	F4Q14	Baird
Net Revenues	\$ 473,189	\$ 485,073	(2%)	\$ 483,546	(2%)	\$ 481,100	(2%)			
Educational Services_	249,729	256,073	(2%)	264,215	(5%)					
Gross Profit	222,175	229,000	(3%)	219,330	1%			47.0%	47.2%	45.4%
Student Services/Administration	175,407	169,716	3%	166,764	5%			37.1%	35.0%	34.5%
EBIT	46,768	59,283	(21%)	52,566	(11%)	48,800	(4%)	9.9%	12.2%	10.9%
Depreciation & Amortization	23,289	22,581	3%	23,289	0%			4.9%	4.7%	4.8%
EBITDA	70,057	81,864	(14%)	75,855	(8%)	70,000	0%	14.8%	16.9%	15.7%
Other Exp (Inc)	(1,707)	(274)	523%	(200)	754%					
Pretax Income	45,061	59,009	(24%)	52,366	(14%)			9.5%	12.2%	10.8%
Taxes	7,568	10,871	(30%)	8,902	(15%)					
Tax Rate	16.8%	18.4%		17.0%						
Net Income (ex. items)	\$ 37,163	\$ 47,686	(22%)	\$ 43,064	(14%)			7.9%	9.8%	8.9%
EPS (ex. items)	\$ 0.57	\$ 0.73	(0.16)	\$0.66	(0.09)	\$0.62	(0.05)			
Diluted Shares	65,213	64,988	0%	65,200	0%					

FQ4 results very weak, and below consensus.

- Revenue of \$473.2mn declined 2% y/y, and was 2% below both the \$481.1mn consensus and our \$483.5mn estimates.
- New enrollment materially as expected, with a few pockets of relative strength, although the metric is volatile on a period-to-period basis, and some of the areas of good percentage growth were off a relatively small base (e.g., Medical International).
- Adj. EBIT of \$46.8mn declined 21% y/y, and was 4% below the \$48.8mn consensus.
- Adj. EPS of \$0.57 also below both the \$0.62 consensus/\$0.66 Baird-est.

Segment Detail

	Quarte	rly Results			
	F4Q15	F4Q14	Change	Baird Est.	Variance
Revenue by Segment (\$ thous)					
Business, Technology, & Management	176,351	215,830	(18%)	185,620	(5%)
Medical & Healthcare	214,053	198,213	8%	219,589	(3%)
International and Professional	83,301	72,124	15%	79,336	5%
Total Revenue	473,705	486,167	(3%)	484,546	(2%)
Mix by Segment					
Business, Technology, & Management	37%	44%		38%	
Medical & Healthcare	45%	41%		45%	
International and Professional	18%	15%		16%	

Sources: Company Data and RW Baird Estimates

All three segments weak, and pockets of growth accompanied by margin contraction.

- Medical & Healthcare adj. EBIT -10% y/y despite 8% revenue growth.
- International & Professional Education adj. EBIT -8% y/y despite 16% revenue growth.
- BTM reported a slight quarterly adj. EBIT loss.

Business, Technology, & Management

DeVry Education Group (NYSE - DV)Business, Technology & Management Segment Results

	Quarte	Quarterly Results					
	F4Q15	F4Q14	Change	Baird Est.	Variance		
Revenue	176,351	215,830	(18%)	185,620	(5%)		
EBIT	(1,870)	3,203	`	-	, ,		
EBIT Margin	-1.1%	1.5%	(250 bp)	0.0%	(110 bp)		

Sources: Company Data and RW Baird Estimates

Medical & Healthcare

DeVry Education Group (NYSE - DV)Medical & Healthcare Segment Results

	Quarte	Quarterly Results					
	F4Q15	F4Q14	Change	Baird Est.	Variance		
Revenue	214,053	215,830	(1%)	219,589	(3%)		
EBIT	31,195	34,772	(10%)	36,232	(14%)		
EBIT Margin	14.6%	16.1%	(150 bp)	16.5%	(190 bp		

Sources: Company Data and RW Baird Estimates

International & Professional

DeVry Education Group (NYSE - DV)International and Professional Segment Results

	Quarter	Quarterly Results					
	F4Q15	F4Q14	Change	Baird Est.	Variance		
Revenue	83,301	72,124	15%	79,336	5%		
EBIT	18,784	20,475	(8%)	19,834	(5%)		
EBIT Margin	22.5%	28.4%	(580 bp)	25.0%	(250 bp		

Sources: Company Data and RW Baird Estimates

Balance Sheet & Cash Flow

DeVry Education Group (NYSE - DV Balance Sheet & Cash Flow	()							
		F4Q15		F3Q15	Q/Q Chg.		F4Q14	Y/Y Chg.
Cash and Equivalents Total Debt Net Cash/Share	\$ \$ \$	367,344 - 5.63	\$ \$ \$	415,350 - 6.39	(12%) NM	\$ \$ \$	361,636 - 5.55	2% NM
Net Receivables Current Deferred Revenue Book value/share	\$ \$ \$	279,148 90,232 24.45	\$ \$ \$	268,363 176,451 24.22	4% (49%) 1%	\$ \$	268,200 91,946 23.62	4% (2%) 4%
Cash Flow from Operations Cap Ex Free Cash Flow	\$	(6,260) (24,406)	\$	(48,754) (21,240)	15%	\$	149,891 (14,183)	NM 72% NM
Free Cash Flow	\$	(30,666)	Ф	(69,994)	NM	\$	135,708	NIVI

Sources: Company Data and RW Baird Estimates

Investment Thesis

Post-secondary market long-term growth market. Post-secondary enrollments are expected to continue to grow intermediate- to long-term based on population growth, a shift in the U.S. economy from manufacturing to service based, and a wage and employment rate gap between people with a post-secondary degree and those with only a high school diploma.

Diversified positioning. DeVry is one of the more diversified private sector education providers. The company's diversified positioning has the potential to lead to more resilient enrollment characteristics, cost sharing and best practices sharing between businesses, a more diversified risk profile, and greater options for long-term capital allocation decisions.

Established brand names. DV operates several established brand names, including its namesake DeVry University. With ~31,000 undergraduates enrolled at 60+ locations, as well as online, DeVry University has strong brand recognition, particularly within its legacy field of technology.

Several attractive growth assets. In addition to its namesake DeVry University, DV also operates several other education assets, including several institutions in Brazil (a faster growing post-secondary education market), as well as assets with high barriers to entry and better labor market trends, including its Caribbean medical schools and Chamberlain College of Nursing.

Regional accreditation. DeVry University and Chamberlain College of Nursing are accredited by North Central Association of Colleges and Schools, one of six regional accreditors. Regional accreditation is the most prestigious type of accreditation.

Risks & Caveats

Competition. The post-secondary education market is highly competitive. Competition is in the form of other private sector for-profit higher education companies such as University of Phoenix, Kaplan, and Strayer, as well as traditional non-profit two and four-year colleges and universities. Online programs are becoming increasingly competitive, with more competitive offerings coming from both

for-profit and non-profit schools, with traditional non-profits sometimes assisted by third-party enablers. Regulatory and accreditation risks. Providers of post-secondary education are subject to regulatory requirements as dictated by the Higher Education Act of 1965. Higher education institutions participating in Title IV funding are required to be accredited by an association recognized by the U.S. Department of Education. Any change in accreditation status, and resulting loss of Title IV eligibility, could have a significant effect on the company's reputation and ability to attract students. Additionally, DV recently received a subpoena and civil investigative demand from the Offices of the Attorney Generals for Illinois and Massachusetts, concerning potential state law implications and guarantees related to student loans and grants.

Economic sensitivity. Post-secondary enrollment trends, especially among working adults, have historically correlated with labor market trends/outlook, consumer confidence, and consumers' views on debt financing; hence, perceived changes in the macroeconomic outlook can impact DV's enrollment trends, positively and negatively.

Increasingly complex business model. Although we believe DV has several attractive assets and believe there are several potential benefits to operating a more diversified model, an increasingly complex model adds execution risk.

Funding risk. While the lending environment has improved since the height of the credit crunch in 2008, the availability of third-party loans for sub-prime students remains weak. In addition, the changes to Pell Grants including the elimination of year-round Pell and changes in Pell Grant eligibility create additional funding uncertainty (and resulted in DV increasing its scholarships). Finally, given US Federal Government fiscal challenges, we believe that continued expansion of Title IV programs could face increasing scrutiny in the future.

Company Description

DeVry Inc., founded in 1931, is a leading provider of private sector education services, including post-secondary education, virtual schools for grades 6-12, and test preparation services. DV operates three segments: "Business, Technology and Management", which includes DeVry University undergraduate and graduate (Keller); "Medical and Healthcare" which includes Ross University medical and veterinary schools, American University of the Caribbean, Chamberlain College of Nursing and Carrington; and "International and Professional Education", which includes DeVry Brazil, and the professional exam review and training operations of Becker Professional Review (Becker CPA Review, ATC International, Falcon Physician Reviews). Combined post-secondary enrollment was approximately 135,308 for the quarter ending June 30.



DeVry Education Group (NYSE - DV)

August 18, 2015 Fiscal year ends: June

Figures in 000s, except per share data

Jeffrey P. Meuler, CFA 414.298.7694 Nick Nikitas, CFA 312.609.5425

Income Statement	2011	2012	2013RE		20	14		2014		20	15		2015		201	6E		2016E
income statement	2011	2012	2013KL	1Q14	2Q14	3Q14	4Q14	2014	1Q15	2Q15	3Q15	4Q15	2013	1Q16E	2Q16E	3Q16E	4Q16E	2010L
Net Revenues	\$ 2,182,371	\$ 2,071,793	\$ 1,964,375	\$ 450,913	\$ 491,269	\$ 496,117	\$ 485,073	\$ 1,923,372	\$ 462,044	\$ 484,880	\$ 489,830	\$ 473,189	\$ 1,909,943	\$ 437,987	\$ 462,491	\$ 468,723	\$ 448,045	\$ 1,817,247
Educational Services	925,504	975,642	962,611	241,737	242,997	242,631	256,073	986,435	246,331	250,809	253,186	249,729	1,001,375	245,273	246,279	236,758	232,857	961,167
Gross Profit	1,256,867	1,096,151	1,001,764	206,180	248,272	253,486	229,000	936,937	215,713	234,071	236,649	222,175	908,568	192,714	216,212	231,965	215,189	856,080
Student services/administration	762,692	808,400	762,714	189,158	184,924	183,949	169,716	727,747	177,753	174,913	180,212	175,407	708,285	166,308	164,524	170,103	163,846	664,781
Income from Operations	494,175	287,751	239,049	17,022	63,348	69,537	59,283	209,190	37,960	59,118	56,437	46,768	200,283	26,406	51,688	61,862	51,342	191,298
Interest / other income (expense)	257	(1,794)	(1,959)	(417)	(742)	(468)	(274)	(1,901)	4	(52)	(1,495)	(1,707)	(3,250)	(1,707)	(1,707)	(1,707)	(1,707)	(6,828)
Income before income taxes	494,432	285,957	237,090	16,605	62,606	69,069	59,009	207,289	37,964	59,066	54,942	45,061	197,033	24,699	49,981	60,155	49,635	184,470
Income tax expense	163,602	81,289	49,668	2,360	10,401	12,918	10,871	36,550	7,075	9,767	9,430	7,568	33,840	4,569	9,246	11,129	9,183	34,127
Minority interest	(427)	(816)	(2,054)	45	(253)	(19)	(452)	(679)	3	(389)	(84)	(330)	(800)	175	(700)	(300)	(400)	(1,225)
Income (ex. items)	330,403	203,852	185,368	14,200	51,952	56,132	47,686	170,060	30,892	48,910	45,428	37,163	162,393	20,305	40,034	48,727	40,053	149,118
Weighted average shares outstanding	70,620	67,705	64,611	63,983	64,719	64,841	64,988	64,853	65,429	65,470	65,265	65,213	65,344	65,148	65,083	65,018	64,953	65,050
EPS (ex. items)	\$ 4.68	\$ 3.01	\$ 2.87	\$ 0.22	\$ 0.80	\$ 0.87	\$ 0.73	\$ 2.62	\$ 0.47	\$ 0.75	\$ 0.70	\$ 0.57	\$ 2.49	\$ 0.31	\$ 0.62	\$ 0.75	\$ 0.62	\$ 2.29
CAL EPS EPS before extraordinary items	\$4.07	\$2.82	\$2.48					\$2.82					\$2.19					
Dividend per Share	\$0.24	\$0.30	\$0.34		\$0.17		\$0.17	\$0.34		\$0.17		\$0.17	\$0.34		\$0.17		\$0.17	\$0.34
% change	20%	25%	13%		0%		0%	0%		0%		0%	0%		0%		0%	0%
% of Sales																		
Gross Margin	57.6%	52.9%	51.0%	45.7%	50.5%	51.1%	47.2%	48.7%	46.7%	48.3%	48.3%	47.0%	47.6%	44.0%	46.7%	49.5%	48.0%	47.1%
Student services/administration	34.9%	39.0%	38.8%	41.9%	37.6%	37.1%	35.0%	37.8%	38.5%	36.1%	36.8%	37.1%	37.1%	38.0%	35.6%	36.3%	36.6%	36.6%
Operating Margin	22.6%	13.9%	12.2%	3.8%	12.9%	14.0%	12.2%	10.9%	8.2%	12.2%	11.5%	9.9%	10.5%	6.0%	11.2%	13.2%	11.5%	10.5%
Pretax Margin	22.7%	13.8%	12.1%	3.7%	12.7%	13.9%	12.2%	10.8%	8.2%	12.2%	11.2%	9.5%	10.3%	5.6%	10.8%	12.8%	11.1%	10.2%
Net Margin (ex. items)	15.1%	9.8%	9.4%	3.1%	10.6%	11.3%	9.8%	8.8%	6.7%	10.1%	9.3%	7.9%	8.5%	4.6%	8.7%	10.4%	8.9%	8.2%
% Change																		
Total Revenue	14.0%	-5.1%	NM	-6.0%	-1.9%	-1.5%	1.1%	-2.1%	2.5%	-1.3%	-1.3%	-2.4%	-0.7%	-5.2%	-4.6%	-4.3%	-5.3%	-4.9%
Gross Margin	15.4%	-12.8%	NM	-14.3%	-4.8%	-4.8%	-2.2%	-6.5%	4.6%	-5.7%	-6.6%	-3.0%	-3.0%	-10.7%	-7.6%	-2.0%	-3.1%	-5.8%
Operating Income	20.3%	-41.8%	NM	-65.6%	-15.6%	-7.4%	50.3%	-12.5%	123.0%	-6.7%	-18.8%		-4.3%	-30.4%	-12.6%	9.6%	9.8%	-4.5%
Pretax Income	19.8%	-42.2%	NM	-65.8%	-16.0%	-7.6%	50.2%	-12.6%	128.6%	-5.7%	-20.5%	-23.6%	-4.9%	-34.9%	-15.4%	9.5%	10.2%	-6.4%
Net Income (ex. items)	18.0%	-38.3%	NM	-58.4%	-10.0%	-5.4%		-8.3%	117.5%	-5.9%	-19.1%	-22.1%	-4.5%	-34.3%	-18.1%	7.3%	7.8%	-8.2%
Average shares	-2.3%	-4.1%	NM	-1.7%	0.6%	0.9%	1.9%	0.4%	2.3%	1.2%	0.7%	0.3%	0.8%	-0.4%	-0.6%	-0.4%	-0.4%	-0.5%
EPS (ex. items)	20.8%	-35.6%	NM	-57.7%	-10.6%	-6.2%	37.0%	-8.6%	112.7%	-6.9%	-19.6%	-22.3%	-5.2%	-34.0%	-17.7%	7.7%	8.2%	-7.8%
Income Tax Rate	33.1%	28.4%	20.9%	14.2%	16.6%	18.7%	18.4%	17.6%	18.6%	16.5%	17.2%	16.8%	17.2%	18.5%	18.5%	18.5%	18.5%	18.5%

Source: Company reports and Robert W. Baird & Co. estimates.

Please refer to "Appendix - Important Disclosures" and Analyst Certification.

2013 results, as presented above, are estimated pro-forma adjusted results ex. Advanced Academics.

DeVry Education Group (NYSE - DV) August 18, 2015

Fiscal year ends: June Figures in 000s, except per share data



Jeffrey P. Meuler, CFA 414.298.7694 Nick Nikitas, CFA 312.609.5425

Segment Details	2011	2015	2013		201	14		2014		201	15		2015		201	6E		2016E
Segment Details	2011	2015	2013	1Q14	2Q14	3Q14	4Q14	2014	1Q15	2Q15	3Q15	4Q15	2013	1Q16E	2Q16E	3Q16E	4Q16E	20100
Revenue	4 400 440	4 000 550	4 000 005	000 000	000 040	0.44.000	045 000	000 040	000 044	040 007	000 000	176.351	704404	400 744	173.980	474.000	4 40 0 40	658.529
Business, Technology, & Management Medical & Healthcare	1,460,146 558.335	1,303,556	1,096,695	232,309	239,913 190,447	241,896	215,830 198,213	929,948	203,641	210,337	203,832 225,427	- ,	794,161	160,711	228,037	174,989	148,849	907,438
International and Professional	163,890	611,953 156,284	672,604 196,576	175,856 43,721	61,430	204,610 50,782	72,124	769,126 228,057	206,012 53,203	213,985 61,224	61,112	214,053 83,301	859,477 258,840	222,163 55,863	61,224	236,428 58,056	220,811 79,136	254,280
	163,690	150,264		(973)	,	,			,			,			,			,
Intersegment Revenue Total	2 402 274	2.071.793	(1,500) 1,964,375	(/	(521)	(1,171)	(1,094) 485,073	(3,759)	(812)	(666) 484.880	(541)	(516) 473.189	(2,535)	(750) 437,987	(750)	(750) 468,723	(750)	(3,000)
lotai	2,182,371	2,071,793	1,964,375	450,913	491,269	496,117	485,073	1,923,372	462,044	484,880	489,830	473,189	1,909,943	437,987	462,491	468,723	448,045	1,817,247
Comparable																		
Business, Technology, & Management	16%	-11%	-16%	-18%	-14%	-15%	-13%	-15%	-12%	-12%	-16%	-18%	-15%	-21%	-17%	-14%	-16%	-17%
Medical & Healthcare	10%	10%	10%	11%	14%	17%	16%	14%	17%	12%	10%	8%	12%	8%	7%	5%	3%	6%
International and Professional	13%	-5%	26%	18%	17%	10%	19%	16%	22%	0%	20%	15%	13%	5%	0%	-5%	-5%	-2%
Total	14%	-5%	-5%	-6%	-2%	-2%	1%	-2%	2%	-1%	-1%	-2%	-1%	-5%	-5%	-4%	-5%	-5%
Mix																		
Business, Technology, & Management	67%	63%	56%	52%	49%	49%	44%	48%	44%	43%	42%	37%	42%	37%	38%	37%	33%	36%
Medical & Healthcare	26%	30%	34%	39%	39%	41%	41%	40%	45%	44%	46%	45%	45%	51%	49%	50%	49%	50%
International and Professional	8%	8%	10%	10%	13%	10%	15%	12%	12%	13%	12%	18%	14%	13%	13%	12%	18%	14%
Total	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
Operating Profit	050 400	000 004	00.400	(5.000)	0.000	00.547	0.000	00.507	405	44.000	5 000	(4.070)	44.050	(0.000)	(4.740)	5.050	(4.400)	(0.044)
Business, Technology, & Management	359,403	206,084	99,123	(5,029)	9,906	22,517	3,203	30,597	135	11,086	5,602	(1,870)	14,953	(8,036)	(1,740)	5,250	(1,488)	(6,014)
Medical & Healthcare	106,965	86,638	117,199	26,235	40,114	45,605	35,674	147,628	38,327	38,092	45,833	31,195	153,447	36,889	41,734	50,434	34,388	163,444
International and Professional	32,684	23,014	47,918	1,080	16,433	7,022	21,137	45,672	4,738	10,491	4,629	18,784	38,642	2,793	12,245	5,806	19,784	40,628
Total	499,052	315,736	264,240	22,286	66,453	75,144	60,014	223,897	43,200	59,669	56,064	48,109	207,042	31,646	52,239	61,489	52,683	198,057
D&A & Other	(4,877)	(23,297)	(25,190)	(5,264)	(3,105)	(5,607)	(731)	(14,707)	(5,240)	(551)	373	(1,341)	(6,759)	(5,240) (0)	(551)	373	(1,341)	(6,759)
Operating Margin														(0)				
Business, Technology, & Management	24.6%	15.8%	9.0%	-2.2%	4.1%	9.3%	1.5%	3.3%	0.1%	5.3%	2.7%	-1.1%	1.9%	-5.0%	-1.0%	3.0%	-1.0%	-0.9%
Medical & Healthcare	19.2%	14.2%	17.4%	14.9%	21.1%	22.3%	18.0%	19.2%	18.6%	17.8%	20.3%	14.6%	17.9%	16.6%	18.3%	21.3%	15.6%	18.0%
International and Professional	19.9%	14.7%	24.4%	2.5%	26.8%	13.8%	29.3%	20.0%	8.9%	17.1%	7.6%	22.5%	14.9%	5.0%	20.0%	10.0%	25.0%	16.0%
Segment Operating Margin	22.9%	15.2%	13.5%	4.9%	13.5%	15.1%	12.4%	11.6%	9.3%	12.3%	11.4%	10.2%	10.8%	7.2%	11.3%	13.1%	11.8%	10.9%
DI																		

Please refer to "Appendix - Important Disclosures" and Analyst Certification.

DeVry Education Group (NYSE - DV) August 18, 2015 Fiscal year ends: June Figures in 000s, except per share data

Jeffrey P. Meuler, CFA 414.298.7694 Nick Nikitas, CFA 312.609.5425

			1		201	A		1		201	5		1		2016	:E	1	
Segment Details	2011	2015	2013	1014	2Q14	3Q14	4Q14	2014	1Q15	2Q15	3Q15	4Q15	2015	1Q16E	2Q16E	3Q16E	4Q16E	2016E
Business, Technology & Management				10(14)	20(14	3417	70(17		14(15)	20(13)	30(13)	79(13		TOLIOL	ZQTOL	JULIOL	7Q10L	
Revenue	1,460,146	1,303,556	1,096,695	232,309	239,913	241,896	215,830	929,948	203,641	210,337	203,832	176,351	794,161	160,711	173,980	174,989	148,849	658,529
% Change	16%	-11%	-16%	-18%	-14%	-15%	-13%	-15%	-12%	-12%	-16%	-18%	-15%	-21%	-17%	-14%	-16%	-17%
Undergraduate Enrollment	69,620	60,907	50,937	43,905	44,806	44,259	42,179	43,787	38,092	38,776	37,344	35,079	37,323	31,620	33,222	32,950	30,246	32,009
% Change	15%	-13%	-16%	-16%	-13%	-14%	-13%	-14%	-13%	-13%	-16%	-17%	-15%	-17%	-14%	-12%	-14%	-14%
Graduate Enrollment	19,120	19,430	17,152	15,888	14,619	14,121	13,312	14,485	13,263	12,833	12,463	11,735	12,574	11,359	11,245	11,591	10,914	11,277
% Change	11%	2%	-12%	-12%	-17%	-17%	-16%	-16%	-17%	-12%	-12%	-12%	-13%	-14%	-12%	-7%	-7%	-10%
Total Enrollment	88,740	80,337	68,089	59,792	59,425	58,380	55,491	58,272	51,355	51,609	49,807	46,814	49,896	42,979	44,467	44,541	41,160	43,287
Average Revenue/Student	16,454	16,226	16,107	3,885	4,037	4,143	3,889	15,959	3,965	4,076	4,092	3,767	15,916	3,739	3,913	3,929	3,616	15,213
% Change	1%	-1%	-1%	-4%	0%	0%	1%	-1%	2%	1%	-1%	-3%	0%	-6%	-4%	-4%	-4%	-4%
Medical and Healthcare																		
Revenue	558,335	611,953	672,604	175,856	190,447	204,610	198,213	769,126	206,012	213,985	225,427	214,053	859,477	222,163	228,037	236,428	220,811	907,438
% Change	10%	10%	10%	11%	14%	17%	16%	14%	17%	12%	10%	8%	12%	8%	7%	5%	3%	6%
DeVry Medical Int. Enrollment	5,794	6,000	6,090	6,019	6,458	6,673	5,915	6,266	6,079	6,406	6,146	5,978	6,152	6,129	6,430	6,184	5,980	6,181
% Change	20%	4%	1%	0%	4%	6%	2%	3%	1%	-1%	-8%	1%	-2%	1%	0%	1%	0%	0%
Chamberlain Enrollment	8,482	10,574	12,675	13,662	15,718	18,152	18,681	16,553	18,709	20,845	23,073	23,065	21,423	22,526	23,971	25,841	25,372	24,428
% Change	61%	25%	20%	21%	29%	34%	36%	31%	37%	33%	27%	23%	29%	20%	15%	12%	10%	14%
Carrington Enrollment	10,226	7,374	7,524	7,706	7,358	7,758	7,353	7,544	7,634	7,444	7,639	7,508	7,556	7,634	7,350	7,588	7,426	7,500
% Change	-12%	-28%	2%	1%	-1%	-2%	3%	0%	-1%	1%	-2%	2%	0%	0%	-1%	-1%	-1%	-1%
Total Enrollment	24,501	23,948	26,289	27,387	29,534	32,583	31,949	30,363	32,421	34,695	36,858	36,551	35,131	36,289	37,752	39,613	38,778	38,108
Average Enrollment	24,397	24,016	25,921	27,006	28,461	31,059	32,266	29,698	32,185	33,558	35,776	36,705	34,556	36,420	37,020	38,683	39,196	37,830
% Change	16%	-2%	8%	11%	12%	16%	19%	15%	19%	18%	15%	14%	16%	13%	10%	8%	7%	9%
Average Revenue/Average # Students	22,886	25,481	25,949	6,512	6,692	6,588	6,143	25,898	6,401	6,377	6,301	5,832	24,872	6,100	6,160	6,112	5,634	23,987
% Change	-5%	11%	2%	0%	1%	1%	-2%	0%	-2%	-5%	-4%	-5%	-4%	-5%	-3%	-3%	-3%	-4%

DeVry Education Group (NYSE - DV) August 18, 2015 Fiscal year ends: June Figures in 000s, except per share data



Jeffrey P. Meuler, CFA 414.298.7694 Nick Nikitas, CFA 312.609.5425

DeVry University Undergraduate - New Students

July 11,016 12,405 13.627	% Change	8,708 10,079	% Change	November 7,283	% Change	January 6.993	% Change	March 7,395	% Change	May 6,700	% Change
12,405		-,	169/	7,283		6 993		7 305		6 700	
,		10.079	4.00/							0,700	
13 627			10%	8,957	23%	8,736	25%	9,078	23%	7,481	12%
13,021	10%	10,060	0%	8,092	-10%	7,217	-17%	7,898	-13%	6,690	-11%
9,026	-34%	7,200	-28%	6,488	-20%	5,593	-23%	6,533	-17%	5,730	-14%
7,532	-17%	6,580	-9%	5,482	-16%	5,330	-5%	5,146	-21%	4,616	-19%
5,674	-25%	6,589	0%	4,824	-12%	4,911	-8%	5,018	-2%	4,388	-5%
4,915	-13%	5,268	-20%	4,201	-13%	4,282	-13%	4,156	-17%	3,817	-13%
4,000	-19%	4,109	-22%	3,361	-20%	3,426	-20%	3,325	-20%	3,054	-20%
9	9,026 7,532 5,674 4,915	9,026 -34% 7,532 -17% 5,674 -25% 4,915 -13%	3,026 -34% 7,200 7,532 -17% 6,580 5,674 -25% 6,589 4,915 -13% 5,268	0,026 -34% 7,200 -28% 7,532 -17% 6,580 -9% 5,674 -25% 6,589 0% 4,915 -13% 5,268 -20%	0,026 -34% 7,200 -28% 6,488 7,532 -17% 6,580 -9% 5,482 5,674 -25% 6,589 0% 4,824 4,915 -13% 5,268 -20% 4,201	9,026 -34% 7,200 -28% 6,488 -20% 7,532 -17% 6,580 -9% 5,482 -16% 5,674 -25% 6,589 0% 4,824 -12% 4,915 -13% 5,268 -20% 4,201 -13%	7,026 -34% 7,200 -28% 6,488 -20% 5,593 7,532 -17% 6,580 -9% 5,482 -16% 5,330 5,674 -25% 6,589 0% 4,824 -12% 4,911 4,915 -13% 5,268 -20% 4,201 -13% 4,282	9,026 -34% 7,200 -28% 6,488 -20% 5,593 -23% 7,532 -17% 6,580 -9% 5,482 -16% 5,330 -5% 5,674 -25% 6,589 0% 4,824 -12% 4,911 -8% 4,915 -13% 5,268 -20% 4,201 -13% 4,282 -13%	0,026 -34% 7,200 -28% 6,488 -20% 5,593 -23% 6,533 7,532 -17% 6,580 -9% 5,482 -16% 5,330 -5% 5,146 5,674 -25% 6,589 0% 4,824 -12% 4,911 -8% 5,018 4,915 -13% 5,268 -20% 4,201 -13% 4,282 -13% 4,156	9,026 -34% 7,200 -28% 6,488 -20% 5,593 -23% 6,533 -17% 7,532 -17% 6,580 -9% 5,482 -16% 5,330 -5% 5,146 -21% 5,674 -25% 6,589 0% 4,824 -12% 4,911 -8% 5,018 -2% 4,915 -13% 5,268 -20% 4,201 -13% 4,282 -13% 4,156 -17%	9,026 -34% 7,200 -28% 6,488 -20% 5,593 -23% 6,533 -17% 5,730 7,532 -17% 6,580 -9% 5,482 -16% 5,330 -5% 5,146 -21% 4,616 5,674 -25% 6,589 0% 4,824 -12% 4,911 -8% 5,018 -2% 4,388 4,915 -13% 5,268 -20% 4,201 -13% 4,282 -13% 4,156 -17% 3,817

2015

DeVry University Undergraduate - Continuing Students/Persistence

Devis Only	ersity officergrad	Juale - Col	nunuing Students	/r ei 313tei i	C C							
Years	July	Pers.	September	Pers.	November	Pers.	January	Pers.	March	Pers.	May	Pers.
F2009	31.359		41.889	99%	41.459	82%	46.323	95%	42,492	80%	47.892	96%
F2010	39,602	73%	51,734	99%	50,831	82%	57,348	96%	54,097	82%	60,402	96%
F2011	50,528	74%	63,093	98%	61,215	84%	66,122	95%	59,476	81%	63,703	95%
F2012	50,940	72%	58,733	98%	53,615	81%	56,842	95%	50,425	81%	54,314	95%
F2013	42,971	72%	49,506	98%	44,033	79%	47,808	97%	42,391	80%	44,226	93%
F2014	36,700	75%	40,377	95%	38,902	83%	40,186	92%	37,565	83%	37,589	88%
F2015	32,295	77%	34,589	93%	34,034	85%	33,640	88%	32,032	84%	30,707	85%
F2016E	27,293	79%	28,164	90%	30,336	94%	30,327	90%	28,020	83%	26,643	85%
	,		,		,		,		,		,	

DeVry University Undergraduate - Total Students

Devis Only	ersity officers	laduate - lot	ai Otudenta									
Years	July	% Change	September	% Change	November	% Change	January	% Change	March	% Change	May	% Change
F2009	42.375		50.597		48,742		53.316		49.887		54.592	
F2010	52,007	23%	61,813	22%	- ,	23%	66,084	24%	63,175	27%	67,883	24%
F2011	64,155	23%	73,153	18%	69,307	16%	73,339	11%	67,374	7%	70,393	4%
F2012	59,966	-7%	65,933	-10%	60,103	-13%	62,435	-15%	56,958	-15%	60,044	-15%
F2013	50,503	-16%	56,086	-15%	49,515	-18%	53,138	-15%	47,537	-17%	48,842	-19%
F2014	42,374	-16%	46,966	-16%	43,726	-12%	45,097	-15%	42,583	-10%	41,977	-14%
F2015	37,210	-12%	39,857	-15%	38,235	-13%	37,922	-16%	36,188	-15%	34,524	-18%
F2016E	31,293	-16%	32,273	-19%	33,697	-12%	33,753	-11%	31,345	-13%	29,696	-14%

DeVry Graduate Coursetakers*

Years	July	% Change	September	% Change	November	% Change	January	% Change	March	% Change	May	% Change
F2009	16,017	14%	17,799	12%	17,803	14%	19,475	12%	19,357	14%	18,822	14%
F2010	17,991	12%	20,496	15%	20,734	16%	22,679	16%	22,343	15%	22,103	17%
F2011	21,165	18%	23,389	14%	23,199	12%	24,784	9%	24,406	9%	23,802	8%
F2012	21,576	2%	23,937	2%	23,264	0%	24,029	-3%	23,366	-4%	23,802	0%
F2013	19,635	-9%	22,072	-8%	19,540	-16%	21,131	-12%	19,075	-18%	18,836	-21%
F2014	16,107	-18%	17,925	-19%	16,778	-14%	17,322	-18%	16,192	-15%	15,866	-16%
F2015	13,845	-14%	15,532	-13%	15,136	-10%	15,108	-13%	14,651	-10%	13,798	-13%
F2016E	12,084	-13%	13,202	-15%	14,076	-7%	14,050	-7%	13,625	-7%	12,832	-7%

^{*}NOTE: Graduate coursetakers mean number of courses taken. Graduate students take 1.2 courses on average.

Fiscal year ends: June Figures in 000s, except per share data

Jeffrey P. Meuler, CFA 414.298.7694 Nick Nikitas, CFA 312.609.5425

Chamberlain College of Nursing - Total Students

Years	July	% Change	September	% Change	November	% Change	January	% Change	March	% Change	May	% Change
F2009	2,465		2,676		3,250		3,472		3,709		3,888	
F2010	4,107	67%	4,753	78%	5,302	63%	5,833	68%	6,322	70%	6,595	70%
F2011	6,732	64%	7,587	60%	8,396	58%	9,044	55%	9,440	49%	9,690	47%
F2012	9,374	39%	10,029	32%	10,619	26%	10,888	20%	11,321	20%	11,214	16%
F2013	10,852	16%	12,050	20%	12,247	15%	13,714	26%	13,235	17%	13,953	24%
F2014	12,648	17%	15,690	30%	15,732	28%	18,136	32%	18,185	37%	18,929	36%
F2015	17,603	39%	20,920	33%	20,807	32%	23,055	27%	23,108	27%	23,044	22%
F2016E	21,760	24%	24,058	15%	23,928	15%	26,052	13%	25,419	10%	25,348	10%

Carrington Colleges - New Students

FQ1	% Change	FQ2	% Change	FQ3	% Change	FQ4	% Change
3,755		2,688		3,629		2,945	
4,763	27%	2,740	2%	3,947	9%	3,144	7%
3,816	-20%	2,379	-13%	2,808	-29%	2,033	-35%
2,548	-33%	1,565	-34%	2,035	-28%	1,632	-20%
3,396	33%	1,763	13%	2,391	17%	1,607	-2%
2,733	-20%	1,706	-3%	2,247	-6%	1,766	10%
2,623	-4%	1,951	14%	2,187	-3%	2,771	57%
2,754	5%	1,853	-5%	2,296	5%	2,494	-10%
	3,755 4,763 3,816 2,548 3,396 2,733 2,623	3,755 4,763 27% 3,816 -20% 2,548 -33% 3,396 33% 2,733 -20% 2,623 -4%	3,755 2,688 4,763 27% 2,740 3,816 -20% 2,379 2,548 -33% 1,565 3,396 33% 1,763 2,733 -20% 1,706 2,623 -4% 1,951	3,755 2,688 4,763 27% 2,740 2% 3,816 -20% 2,379 -13% 2,548 -33% 1,565 -34% 3,396 33% 1,763 13% 2,733 -20% 1,706 -3% 2,623 -4% 1,951 14%	3,755 2,688 3,629 4,763 27% 2,740 2% 3,947 3,816 -20% 2,379 -13% 2,808 2,548 -33% 1,565 -34% 2,035 3,396 33% 1,763 13% 2,391 2,733 -20% 1,706 -3% 2,247 2,623 -4% 1,951 14% 2,187	3,755 2,688 3,629 4,763 27% 2,740 2% 3,947 9% 3,816 -20% 2,379 -13% 2,808 -29% 2,548 -33% 1,565 -34% 2,035 -28% 3,396 33% 1,763 13% 2,391 17% 2,733 -20% 1,706 -3% 2,247 -6% 2,623 -4% 1,951 14% 2,187 -3%	3,755 2,688 3,629 2,945 4,763 27% 2,740 2% 3,947 9% 3,144 3,816 -20% 2,379 -13% 2,808 -29% 2,033 2,548 -33% 1,565 -34% 2,035 -28% 1,632 3,396 33% 1,763 13% 2,391 17% 1,607 2,733 -20% 1,706 -3% 2,247 -6% 1,766 2,623 -4% 1,951 14% 2,187 -3% 2,771

Carrington Colleges - Continuing Students/Persistence

Years	FQ1	Pers.	FQ2	Pers.	FQ3	Pers.	FQ4	Pers.
F2009	6,101		7,378	75%	7,299	73%	7,531	69%
F2010	7,037	67%	8,521	72%	8,062	72%	8,193	68%
F2011	7,708	68%	8,065	70%	7,399	71%	6,695	66%
F2012	5,774	66%	5,814	70%	5,274	71%	4,854	66%
F2013	4,232	65%	5,642	74%	5,560	75%	5,504	69%
F2014	4,973	70%	5,652	73%	5,511	75%	5,587	72%
F2015	5,011	68%	5,493	72%	5,452	73%	4,737	62%
F2016E	4,880	65%	5.497	72%	5,292	72%	4,933	65%

Carrington Colleges - Total Students

Years	FQ1	% Change	FQ2	% Change	FQ3	% Change	FQ4	% Change
F2009	9.856		10.066		10.928		10.476	
F2010	11,800	20%	11,261	12%	12,009	10%	11,337	8%
F2011	11,524	-2%	10,444	-7%	10,207	-15%	8,728	-23%
F2012	8,322	-28%	7,379	-29%	7,309	-28%	6,486	-26%
F2013	7,628	-8%	7,405	0%	7,951	9%	7,111	10%
F2014	7,706	1%	7,358	-1%	7,758	-2%	7,353	3%
F2015	7,634	-1%	7,444	1%	7,639	-2%	7,508	2%
F2016E	7.634	0%	7,350	-1%	7,588	-1%	7,426	-1%

DeVry Med	dical Internation	nal Total*					DeVry Me	dical Internation	al Continuing	Students/Po	ersistence		
Years	September	% Change	January	% Change	May	% Change	Years	September	% Change	January	% Change	May	% Change
F2009	4,219	9%	4,323	8%	4,448	9%	F2009	3,611	88.9%	3,712	88.0%	3,886	89.9%
F2010	4,601	9%	4,669	8%	5,542	25%	F2010E	3,935	88.5%	3,970	86.3%	5,002	NM
F2011	5,723	24%	5,965	28%	5,885	6%	F2011	5,029	90.7%	5,209	91.0%	5,319	89.2%
F2012	6,082	6%	6,024	1%	5,944	1%	F2012	5,229	88.9%	5,423	89.2%	5,301	88.0%
F2013	6,209	2%	6,318	5%	5,800	-2%	F2013	5,284	88.9%	5,715	92.0%	5,282	83.6%
F2014	6,458	4%	6,673	6%	5,915	2%	F2014	5,480	94.5%	6,091	94.3%	5,360	80.3%
F2015	6,406	-1%	6,146	-8%	5,978	1%	F2015	5,463	92.4%	5,586	87.2%	5,361	87.2%
F2016E	6,430	0%	6,184	1%	5,980	0%	F2016E	5,440	91.0%	5,607	87.2%	5,394	87.2%

DeVry Medical International - New Students*

Years	September	% Change	January	% Change	May	% Change
F2009	608	6%	611	11%	562	17%
F2010	666	10%	699	14%	540	-4%
F2011	694	4%	756	8%	566	5%
F2012	853	23%	601	-21%	643	14%
F2013	925	8%	603	0%	518	-19%
F2014	978	6%	582	-3%	555	7%
F2015	943	-4%	560	-4%	617	11%
F2016E	990	5%	577	3%	586	-5%

DeVry Education Group (NYSE - DV) April 15, 2014 Fiscal year ends: June

Figures in 000s, except per share data



Jeffrey P. Meuler, CFA 414.298.7694 Nick Nikitas, CFA / (312) 609-5425

Balance Sheet	2011	2012	2013	2014	2015	3Q14	4Q14	1Q15	2Q15	3Q15	4Q15
Assets											
Cash and Equivalents	449,720	176,708	199,551	361,636	367,344	400,148	361,636	476,522	383,485	415,350	367,344
Net Receivables	114,689	113,911	139,778	132,621	139,163	161,202	132,621	170,280	89,318	149,586	139,163
Inventory	0	0	0	0	0	0	0	0	0	0	0
Deferred Taxes	24,457	27,845	32,515	39,679	41,458	29,458	39,679	46,741	45,104	45,163	41,458
Other Current	35,784	82,650	42,339	43,155	53,092	47,688	43,155	42,329	54,872	57,822	53,092
Total Current Assets	624,650	401,114	414,183	577,091	601,057	638,496	577,091	735,872	572,779	667,921	601,057
Property Plant and Equipment	468,244	558,977	571,657	555,837	545,874	551,511	555,837	552,414	542,989	544,623	545,874
Intangibles/Other	757,609	878,525	854,057	864,708	927,273	858,858	864,708	846,341	852,098	936,133	927,273
Total Assets	1,850,503	1,838,616	1,839,897	1,997,636	2,074,204	2,048,865	1,997,636	2,134,627	1,967,866	2,148,677	2,074,204
Liabilities and Equity											
Current Debt	0	0	0	0	0	0	0	0	0	0	0
Payables	63,611	63,094	55,131	52,260	63,083	54,594	52,260	68,183	55,737	58,531	63,083
Deferred Revenue	97,894	98,131	97,478	91,946	90,232	194,560	91,946	234,884	66,356	176,451	90,232
Accrued liabilities/Other	154,926	153,984	145,867	164,685	168,594	156,534	164,685	148,198	142,887	164,576	168,594
Total Current Liabilities	316,431	315,209	298,476	308,891	321,909	405,688	308,891	451,265	264,980	399,558	321,909
Long Term Debt & Lease	0	0	0	0	0	0	0	0	0	0	0
Deferred Revenue	0	0	0	0	0	0	0	0	0	0	0
Deferred Taxes/Other	137,801	158,772	143,414	148,959	157,854	143,669	148,959	136,574	138,872	175,073	157,854
Shareholders Equity	1,396,271	1,364,635	1,398,007	1,539,786	1,594,430	1,499,508	1,539,786	1,546,788	1,564,014	1,574,046	1,594,430
Total Liability and Equity	1,850,503	1,838,616	1,839,897	1,997,636	2,074,193	2,048,865	1,997,636	2,134,627	1,967,866	2,148,677	2,074,193

Balance Sheet Analysis	2011	2012	2013	2014E	2015E	3Q14	4Q14	1Q15	2Q15	3Q15	3Q15
Total Debt/Total Capital	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
LT Debt/Equity	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Current Ratio	2.0	1.3	1.4	1.9	1.9	1.6	1.9	1.6	2.2	1.7	1.9
Quick Ratio	1.8	0.9	1.1	1.6	1.6	1.4	1.6	1.4	1.8	1.4	1.6
Days Sales Outstanding	27	29	31	28	28	29	28	27	26	26	26
Working Capital	308,219	85,905	115,707	268,200	279,148	232,808	268,200	284,607	307,799	268,363	279,148
Book Value/Share	\$19.77	\$20.16	\$21.64	\$23.74	\$24.40	\$23.13	\$23.69	\$23.64	\$23.89	\$24.12	\$24.45
Cash/share	\$6.37	\$2.61	\$3.09	\$5.58	\$5.62	\$6.17	\$5.56	\$7.28	\$5.86	\$6.36	\$5.63

Please	refer	to "	Appendix	c - Import	ant Disc	losures'	' and	Analyst	Certific	cation
--------	-------	------	----------	------------	----------	----------	-------	---------	----------	--------


Cash Flow Statement	2011	2012	2013	2014	2015
Net Income	330,403	203,852	185,368	170,060	162,393
+Dep. and Amortization	64,571	88,689	93,250	89,817	90,556
+Deferred Taxes/Other	27,310	32,429	(13,034)	(19,243)	(48,095)
 Working Cap. Changes 	(14,294)	(47,547)	(1.636)	22,288	(1,747)
Cash Flow from Operations	407,990	277,423	263,948	262,922	203,107
-Capital Expenditures	(135,726)	(129,055)	(111,775)	(79,355)	(88,707)
Free Cash Flow	272,264	148,368	152,173	183,567	114,400
Shares (millions)	70,620	67,705	64,611	64,853	65,344
Operating Cash Flow/ Share	5.78	4.10	4.09	4.05	3.11
Free Cash Flow/Share	3.86	2.19	2.36	2.83	1.75

Ratio Analysis	2011	2012	2013	2014	2015
Net Margins (N/S)	15.1%	9.8%	9.4%	8.8%	8.5%
Asset Turnover (S/A)	1.2	1.1	1.1	1.0	0.9
Leverage (A/E)	1.3	1.3	1.3	1.3	1.3
Return on Equity	24.1%	14.8%	13.4%	11.1%	10.2%
Return on Assets	19.0%	11.1%	10.1%	8.9%	8.0%

Valuation Measures		2011	2012	2013	2014	2015
Stock Price (fiscal year)	High	\$ 62.31	\$ 66.55	\$ 34.03	\$ 45.99	\$ 49.18
	Low	\$ 36.34	\$ 26.58	\$ 18.35	\$ 28.32	\$ 30.04
6/30	Close	\$ 58.88	\$ 30.97	\$ 31.02	\$ 42.34	\$ 31.34
Historical P/E	High	13	22	12	18	20
	Low	8	9	6	11	12
Historical P/CF	High	11	16	8	11	16
	Low	6	6	4	7	10

Debt Adj. Market Value	2011	2012	2013	2014	2015
Market Value	4,158,106	2,096,824	2,004,233	2,745,876	2,047,889
ST+LT Debt	0	0	0	0	0
Cash & Equivalents	449,720	176,708	199,551	361,636	367,344
Total Enterprise Value	3,708,386	1,920,116	1,804,682	2,384,240	1,680,545
EBITDA	558,746	376,440	332,299	299,007	290,839
EV/EBITDA	6.6	5.1	5.4	8.0	5.8

Appendix - Important Disclosures and Analyst Certification



1 Robert W. Baird & Co. Incorporated makes a market in the securities of DV.

Robert W. Baird & Co. Incorporated and/or its affiliates expect to receive or intend to seek investment banking related compensation from the company or companies mentioned in this report within the next three months.

Robert W. Baird & Co. Incorporated may not be licensed to execute transactions in all foreign listed securities directly. Transactions in foreign listed securities may be prohibited for residents of the United States. Please contact a Baird representative for more information. Investment Ratings: Outperform (O) - Expected to outperform on a total return, risk-adjusted basis the broader U.S. equity market over the next 12 months. Neutral (N) - Expected to perform in line with the broader U.S. equity market over the next 12 months. Underperform (U) - Expected to underperform on a total return, risk-adjusted basis the broader U.S. equity market over the next 12 months.

Risk Ratings: L - Lower Risk - Higher-quality companies for investors seeking capital appreciation or income with an emphasis on safety. Company characteristics may include: stable earnings, conservative balance sheets, and an established history of revenue and earnings. A - Average Risk - Growth situations for investors seeking capital appreciation with an emphasis on safety. Company characteristics may include: moderate volatility, modest balance-sheet leverage, and stable patterns of revenue and earnings. H - Higher Risk - Higher-growth situations appropriate for investors seeking capital appreciation with the acceptance of risk. Company characteristics may include: higher balance-sheet leverage, dynamic business environments, and higher levels of earnings and price volatility. S - Speculative Risk - High-growth situations appropriate only for investors willing to accept a high degree of volatility and risk. Company characteristics may include: unpredictable earnings, small capitalization, aggressive growth strategies, rapidly changing market dynamics, high leverage, extreme price volatility and unknown competitive challenges.

Valuation, Ratings and Risks. The recommendation and price target contained within this report are based on a time horizon of 12 months but there is no guarantee the objective will be achieved within the specified time horizon. Price targets are determined by a subjective review of fundamental and/or quantitative factors of the issuer, its industry, and the security type. A variety of methods may be used to determine the value of a security including, but not limited to, discounted cash flow, earnings multiples, peer group comparisons, and sum of the parts. Overall market risk, interest rate risk, and general economic risks impact all securities. Specific information regarding the price target and recommendation is provided in the text of our most recent research report.

Distribution of Investment Ratings. As of July 31, 2015, Baird U.S. Equity Research covered 744 companies, with 51% rated Outperform/Buy, 48% rated Neutral/Hold and 1% rated Underperform/Sell. Within these rating categories, 13% of Outperform/Buy-rated and 7% of Neutral/Hold-rated companies have compensated Baird for investment banking services in the past 12 months and/or Baird managed or co-managed a public offering of securities for these companies in the past 12 months.

Analyst Compensation. Analyst compensation is based on: 1) the correlation between the analyst's recommendations and stock price performance; 2) ratings and direct feedback from our investing clients, our institutional and retail sales force (as applicable) and from independent rating services; 3) the analyst's productivity, including the quality of the analyst's research and the analyst's contribution to the growth and development of our overall research effort and 4) compliance with all of Robert W. Baird's internal policies and procedures. This compensation criteria and actual compensation is reviewed and approved on an annual basis by Baird's Research Oversight Committee.

Analyst compensation is derived from all revenue sources of the firm, including revenues from investment banking. Baird does not compensate research analysts based on specific investment banking transactions.

A complete listing of all companies covered by Baird U.S. Equity Research and applicable research disclosures can be accessed at http://www.rwbaird.com/research-insights/research/coverage/research-disclosure.aspx.

You can also call 1-800-792-2473 or write: Robert W. Baird & Co., Equity Research, 777 E. Wisconsin Avenue, Milwaukee, WI 53202.

Analyst Certification. The senior research analyst(s) certifies that the views expressed in this research report and/or financial model accurately reflect such senior analyst's personal views about the subject securities or issuers and that no part of his or her compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report.

Disclaimers

Baird prohibits analysts from owning stock in companies they cover.

This is not a complete analysis of every material fact regarding any company, industry or security. The opinions expressed here reflect our judgment at this date and are subject to change. The information has been obtained from sources we consider to be reliable, but we cannot guarantee the accuracy.

ADDITIONAL INFORMATION ON COMPANIES MENTIONED HEREIN IS AVAILABLE UPON REQUEST

The Dow Jones Industrial Average, S&P 500, S&P 400 and Russell 2000 are unmanaged common stock indices used to measure and report performance of various sectors of the stock market; direct investment in indices is not available.

Baird is exempt from the requirement to hold an Australian financial services license. Baird is regulated by the United States Securities and Exchange Commission, FINRA, and various other self-regulatory organizations and those laws and regulations may differ from Australian laws. This report has been prepared in accordance with the laws and regulations governing United States broker-dealers and not Australian laws.

Copyright 2015 Robert W. Baird & Co. Incorporated Other Disclosures

The information and rating included in this report represent the Analyst's long-term (12 month) view as described above. The research analyst(s) named in this report may at times, discuss, at the request of our clients, including Robert W. Baird & Co. salespersons and traders, or may have discussed in this report, certain trading strategies based on catalysts or events that may have a near-term impact on the market price of the equity securities discussed in this report. These trading strategies may differ from the analysts' published price target or rating for such securities. Any such trading strategies are distinct from and do not affect the analysts' fundamental long-term (12 month) rating for such securities, as described above. In addition, Robert W. Baird & Co. Incorporated and/or its affiliates (Baird) may provide to certain clients additional or research supplemental products or services, such as outlooks, commentaries and other detailed analyses, which focus on covered stocks, companies, industries or sectors. Not all clients who receive our standard company-specific research reports are eligible to receive these additional or supplemental products or services. Baird determines in its sole discretion the clients who will receive additional or supplemental products or services, in light of various factors including the size and scope of the client relationships. These additional or supplemental products or services may feature different analytical or research techniques and information than are contained in Baird's standard research reports. Any ratings and recommendations contained in more broadly disseminated standard research reports.

UK disclosure requirements for the purpose of distributing this research into the UK and other countries for which Robert W. Baird Limited holds an ISD passport.

This report is for distribution into the United Kingdom only to persons who fall within Article 19 or Article 49(2) of the Financial Services and Markets Act 2000 (financial promotion) order 2001 being persons who are investment professionals and may not be distributed to private clients. Issued in the United Kingdom by Robert W. Baird Limited, which has an office at Finsbury Circus House, 15 Finsbury Circus, London EC2M 7EB, and is a company authorized and regulated by the Financial Conduct Authority. For the purposes of the Financial Conduct Authority requirements, this investment research report is classified as objective.

Robert W. Baird Limited ("RWBL") is exempt from the requirement to hold an Australian financial services license. RWBL is regulated by the Financial Conduct Authority ("FCA") under UK laws and those laws may differ from Australian laws. This document has been prepared in accordance with FCA requirements and not Australian laws.

Dividend Yield. As used in this report, the term "dividend yield" refers, on a percentage basis, to the historical distributions made by the issuer relative to its current market price. Such distributions are not guaranteed, may be modified at the issuer's discretion, may exceed operating cash flow, subsidized by borrowed funds or include a return of investment principal.

Ask the analyst a question

Click here to unsubscribe